TNYA Stock Price, Tenaya Therapeutics, . Quote, Chart

Market Summary

USD4.66+0.41

Delayed

9.65%

TNYA Stock Price

View Fullscreen

TNYA RSI Chart

TNYA Valuation

Market Cap

365.9M

Price/Earnings (Trailing)

-2.94

EV/EBITDA

-2.65

Price/Free Cashflow

-3.6

MarketCap/EBT

-2.94

TNYA Price/Earnings (Trailing)

TNYA Profitability

Return on Equity

-78.77%

Return on Assets

-67.39%

Free Cashflow Yield

-27.77%

TNYA Fundamentals

TNYA Earnings

Earnings (TTM)

-124.6M

Earnings Growth (Yr)

-1.55%

Earnings Growth (Qtr)

-7.57%

Breaking Down TNYA Revenue

Last 7 days

11.0%

Last 30 days

8.4%

Last 90 days

-26.3%

Trailing 12 Months

-35.5%

How does TNYA drawdown profile look like?

TNYA Financial Health

Current Ratio

6.72

TNYA Investor Care

Shares Dilution (1Y)

17.42%

Diluted EPS (TTM)

-1.65

Tracking the Latest Insider Buys and Sells of Tenaya Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	hoey timothy	sold	-23,101	7.0003	-3,300	chief scientific officer
Feb 23, 2024	tingley whittemore	acquired	-	-	35,000	chief medical officer
Feb 23, 2024	ali faraz	acquired	-	-	85,000	chief executive officer
Feb 23, 2024	hoey timothy	acquired	-	-	12,500	chief scientific officer
Feb 23, 2024	patterson leone d	acquired	-	-	35,000	chief fin. and bus. officer
Feb 20, 2024	hoey timothy	sold	-35,046	5.33506	-6,569	chief scientific officer
Feb 16, 2024	patterson leone d	sold	-30,477	5.86	-5,201	chief fin. and bus. officer
Feb 16, 2024	hoey timothy	sold	-27,430	5.86	-4,681	chief scientific officer
Feb 16, 2024	ali faraz	sold	-37,257	5.86	-6,358	chief executive officer
Feb 16, 2024	tingley whittemore	sold	-38,090	5.86	-6,500	chief medical officer

Which funds bought or sold TNYA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	293	267,945	317,974	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-344	24,429	-%
May 15, 2024	Man Group plc	sold off	-100	-124,870	-	-%
May 15, 2024	Squarepoint Ops LLC	reduced	-55.4	-132,040	339,364	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	new	-	993,700	993,700	0.01%
May 15, 2024	Integrated Wealth Concepts LLC	unchanged	-	29,850	78,450	-%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	added	4.5	12,255,100	30,098,900	0.39%
May 15, 2024	Jasper Ridge Partners, L.P.	unchanged	-	20,398	53,608	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-25.38	333,132	1,961,780	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-20.9	130,081	599,881	-%

Are Funds Buying or Selling TNYA?

Are funds buying TNYA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TNYA

No. of Funds

Unveiling Tenaya Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	6.7%	4,544,543	SC 13G/A
Feb 14, 2024	column group iii, lp	5.7%	4,414,720	SC 13D/A
Feb 14, 2024	rtw investments, lp	0%	0	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.99%	6,948,236	SC 13G/A
Jan 31, 2024	blackrock inc.	5.6%	3,786,824	SC 13G
Feb 21, 2023	column group iii, lp	6.9%	4,414,720	SC 13D/A
Feb 14, 2023	ra capital management, l.p.	9.99%	6,428,483	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	6.7%	4,472,202	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Dec 07, 2022	casdin capital, llc	9.9%	6,427,200	SC 13D/A

Recent SEC filings of Tenaya Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
Apr 17, 2024	ARS	ARS
Apr 17, 2024	DEF 14A	DEF 14A
Apr 17, 2024	DEFA14A	DEFA14A
Mar 18, 2024	10-K	Annual Report
Mar 18, 2024	8-K	Current Report
Mar 06, 2024	4	Insider Trading
Mar 05, 2024	144	Notice of Insider Sale Intent
Feb 27, 2024	4	Insider Trading

Peers (Alternatives to Tenaya Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Tenaya Therapeutics, Inc. News

Latest updates

Tenaya Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	8.4%	185	171	193	221	245	279	226	256	281	314	332	157	148
Current Assets	15.3%	129	112	127	139	155	194	157	186	214	255	285	113	130
Cash Equivalents	29.8%	59.00	46.00	82.00	76.00	73.00	95.00	34.00	31.00	26.00	38.00	117	112	129
Net PPE	-4.3%	41.00	43.00	45.00	47.00	49.00	51.00	52.00	53.00	49.00	43.00	31.00	25.00	17.00
Liabilities	-14.1%	27.00	31.00	29.00	31.00	30.00	36.00	30.00	32.00	32.00	36.00	28.00	25.00	9.00
Current Liabilities	-15.7%	19.00	23.00	19.00	21.00	19.00	24.00	18.00	19.00	19.00	22.00	14.00	10.00	5.00
Shareholder's Equity	13.5%	158	139	165	190	215	243	196	224	249	279	304	-	-
Retained Earnings	-8.0%	-435	-403	-373	-344	-310	-279	-245	-215	-186	-155	-129	-111	-82.81
Additional Paid-In Capital	9.4%	594	543	538	534	526	523	443	440	436	434	433	3.00	2.00
Shares Outstanding	-100.0%	-	68.00	74.00	73.00	73.00	67.00	41.00	41.00	41.00	41.00	27.00	-	1.00
Float	-	-	-	-	272	-	-	-	156	-	528	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-30.7%	-28,660	-21,924	-23,638	-26,220	-30,290	-22,682	-27,556	-25,430	-28,756	-16,347	-16,657	-12,019	-15,789	-	-	-
Share Based Compensation	7.0%	4,224	3,949	4,015	3,831	3,514	3,187	3,174	3,012	2,094	1,048	968	502	432	-	-	-
Cashflow From Investing	69.9%	-4,489	-14,919	30,488	25,085	8,061	5,974	31,034	30,210	16,434	-62,580	-168,425	-3,236	-4,323	-	-	-
Cashflow From Financing	12506.7%	46,771	371	-	4,179	-501	77,486	6.00	260	15.00	-21.00	190,274	-1,298	20,015	-	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	3.00	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TNYA Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 25,055	$ 25,605
General and administrative	8,707	8,118
Total operating expenses	33,762	33,723
Loss from operations	(33,762)	(33,723)
Other income, net:
Interest income	1,452	1,973
Other income, net	82	13
Total other income, net	1,534	1,986
Net loss before income tax expense	(32,228)	(31,737)
Net loss	(32,228)	(31,737)
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable securities	(14)	258
Comprehensive loss	$ (32,242)	$ (31,479)
Net loss per share, basic	$ (0.4)	$ (0.43)
Net loss per share, diluted	$ (0.4)	$ (0.43)
Weighted-average shares used in computing net loss per share, basic	80,982,326	73,097,889
Weighted-average shares used in computing net loss per share, diluted	80,982,326	73,097,889

TNYA Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 59,303	$ 45,681
Short-term investments in marketable securities	62,946	58,961
Prepaid expenses and other current assets	6,450	6,940
Total current assets	128,699	111,582
Property and equipment, net	41,396	43,277
Operating lease right-of-use assets	9,177	9,979
Other noncurrent assets	5,627	5,677
Total assets	184,899	170,515
Current liabilities:
Accounts payable	6,659	5,630
Accrued and other current liabilities	8,435	12,784
Operating lease liabilities, current	4,064	4,319
Total current liabilities	19,158	22,733
Operating lease liabilities, noncurrent	7,302	8,105
Other noncurrent liabilities	259	253
Total liabilities	26,719	31,091
Commitments and contingencies (Note 5)
Stockholders' equity:
Common stock	8	7
Additional paid-in capital	593,802	542,805
Accumulated other comprehensive loss	(120)	(106)
Accumulated deficit	(435,510)	(403,282)
Total stockholders' equity	158,180	139,424
Total liabilities and stockholders' equity	$ 184,899	$ 170,515

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301, a small molecule for heart failure with preserved ejection fraction; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy. It also develops an adeno-associated virus-based gene therapy designed to deliver the dwarf open reading frame gene in the heart for dilated cardiomyopathy; and reprogramming program for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

CEO	Mr. Faraz Ali M.B.A.
WEBSITE	tenayatherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	141

Tenaya Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Tenaya Therapeutics, Inc.? What does TNYA stand for in stocks?

TNYA is the stock ticker symbol of Tenaya Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tenaya Therapeutics, Inc. (TNYA)?

As of Fri May 17 2024, market cap of Tenaya Therapeutics, Inc. is 365.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNYA stock?

You can check TNYA's fair value in chart for subscribers.

What is the fair value of TNYA stock?

You can check TNYA's fair value in chart for subscribers. The fair value of Tenaya Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tenaya Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TNYA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tenaya Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TNYA is over valued or under valued. Whether Tenaya Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Tenaya Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNYA.